A company wrestling with the problem of how to kill harmful bacteria while retaining bacteria beneficial to the body has raised crucial new investment of £500k.
Aspiring biotechnology entrepreneurs from the University of Cambridge won the Biotechnology Young Entrepreneurs Scheme (YES) 2012 after a day of tough competition in London.
Vernalis plc, the Cambridge UK biotechnology company, has reported successful results from a Receptor Occupancy (RO) study with V81444, its A2A antagonist which has potential applications in Parkinson's disease and other CNS indications.
A Norwich company is close to completing Phase III trials on an under-the-tongue spray which could dramatically reduce child malaria deaths.
Antibody technology pioneers from Cambridge today took their medical revolution from the UK to California.
A Cambridge UK medical technology business has been honoured by the European Union with an award to celebrate its work researching new treatments for blood cancer.
BioFocus has received an unspecified development milestone payout under its medicinal chemistry deal with UCB.
Researchers have defined the gene responsible for a rare developmental disorder in children and hope that follow-on tests could ultimately lead to therapies.
- Plenty in the pot for cannabis-based drug firm
- Cambridge boost for bypass surgery patients
- Avita taps $multibillion market
- Vectura set for fresh growth spurt
- Abcam boss backs stem cell venture
- Fertility firm’s cash to trigger baby boom
- Top medic boosts PneumaCare’s US growth
- Cambridge software a sound investment
- Cambridge brain surgeons pioneer 3D technology
- Cambridge sweeps board in medtech awards
- Fertility firm on top of the world
- Valley-Cambridge personalised medicines alliance
Page 52 of 126